InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,268.56
(
0.14%
)
US TECH 100
22,227.20
(
0.27%
)
Dow Jones
44,459.65
(
0.20%
)
Brent Oil
68.46
(
-0.21%
)
Bitcoin
117,623.52
(
-1.90%
)
Post# of 493776
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

hnbadger1

Send PM Follow Ignore
Followers 32
Posts 1799
Boards Moderated 0
Alias Born 05/03/2012

hnbadger1

Re: Guzzi62 post# 488612

Friday, 04/25/2025 5:38:42 AM

Friday, April 25, 2025 5:38:42 AM

Post# of 493776
This from Factanonverba on stock twits-
“The 14% improvement in cognitive function and an 8% improvement in daily activities after 70 weeks of treatment with blarcamesine are detailed in an Anavex Life Sciences press release dated March 16, 2021.
Mini-Mental State Examination (MMSE) scores improved by +3.0 points, representing a 14% improvement from baseline.
Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scores increased by +6.0 points, equating to an 8% improvement from baseline.
Third time I see this in EU articles (one in German, one in French, one in Italian).”
Bullish
Bullish
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News
InvestorsHub NewsWire

Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • BLEG • Jul 14, 2025 1:23 PM

VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM

Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM

Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM

Start posting your company's news
Only $200 per official company press release!